ReviewHuman mutation2011
Databases in the area of pharmacogenetics.
Review in Human mutation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 61 citations in OpenAlex.
- Developmentally dynamic chromatin state at loci regulating organ crosstalk by remote sensing and signaling.Epigenetics & chromatin · 2025Article
- ESR1 Variants and Subcontinental Genomic Ancestry: Insights from the 1000 Genomes Project and Native American Populations.Clinical pharmacology and therapeutics · 2025Article
- Rare variants in pharmacogenes influence clozapine metabolism in individuals with schizophrenia.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2024Article
- Development and application of a computable genotype model in the GA4GH Variation Representation Specification.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2023Article
- Joint Analysis of Phenotypic and Genomic Diversity Sheds Light on the Evolution of Xenobiotic Metabolism in Humans.Genome biology and evolution · 2022Article
- Genetic Variation among Pharmacogenes in the Sardinian Population.International journal of molecular sciences · 2022Article
- Prevalence of five pharmacologically most importantArhiv za higijenu rada i toksikologiju · 2021Article
- Genetic variation of pharmacogenomic VIP variants in Zhuang nationality of southern China.The pharmacogenomics journal · 2021Article
- Efficacy of computational predictions of the functional effect of idiosyncratic pharmacogenetic variants.PeerJ · 2021Article
- Polypharmacy: a healthcare conundrum with a pharmacogenetic solution.Critical reviews in clinical laboratory sciences · 2019Article
- Genetic variation in the Estonian population: pharmacogenomics study of adverse drug effects using electronic health records.European journal of human genetics : EJHG · 2019Article
- Review
- Concepts Driving Pharmacogenomics Implementation Into Everyday Healthcare.Pharmacogenomics and personalized medicine · 2019Review
- Natural variation in a single amino acid substitution underlies physiological responses to topoisomerase II poisons.PLoS genetics · 2017Article
- Genetic polymorphisms of pharmacogenomic VIP variants in the Mongol of Northwestern China.BMC genetics · 2016Article
- Article
- Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease.Pharmacogenomics · 2014Article
- Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancer.Physiological genomics · 2014Review
- Deciphering next-generation pharmacogenomics: an information technology perspective.Open biology · 2014Article
- PharmGKB: the Pharmacogenomics Knowledge Base.Methods in molecular biology (Clifton, N.J.) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
In the area of pharmacogenetics and personalized health care it is obvious that databases, providing important information of the occurrence and consequences of variant genes encoding drug metabolizing enzymes, drug transporters, drug targets, and other proteins of importance for drug response or toxicity, are of critical value for scientists, physicians, and industry. The primary outcome of the pharmacogenomic field is the identification of biomarkers that can predict drug toxicity and drug response, thereby individualizing and improving drug treatment of patients. The drug in question and the polymorphic gene exerting the impact are the main issues to be searched for in the databases. Here, we review the databases that provide useful information in this respect, of benefit for the development of the pharmacogenomic field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.